title: [Disseminated intravascular coagulation].
abstract: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic formation of microthrombi and fibrin deposition in the vasculature. Cancer is one of the leading cause of DIC, which often complicates bleeding tendency and organ dysfunction. Even though DIC therapy is expectant, it is still important, since the bleeding tendency limits the quality of patients' life remarkably. Heparin, low molecular weight heparin, danaparoid, protease inhibitors for coagulation factors and antithrombin III are the choices for DIC. However, since the selection of the drugs is different depending on the basal disease, it is important to understand the pathophysiology of the individual situation. In general, protease inhibitors is recommended for 'fibrinolysis dominant DIC' like DIC associated with leukemia and terminal stage solid cancer, in contrast, danaparoid and antithrombin III are the first choice for 'coagulation dominant DIC' like sepsis. Supplement of concentrated platelets and fresh frozen should be limited for the patients whose primary disease can be controlled.
authors.affiliation: Department of Surgery, Juntendo University, Urayasu Hospital.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Iba
authors.forename: Akio
authors.initials: A
authors.lastname: Kidokoro
mesh_terms: D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D009369:Neoplasms / Q000150:complications*